ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
More News
Inside Jennifer Eckhart’s Lawsuit Against Fox News Alum Ed Henry
Content warning: This story discusses suicide. It was the news story Jennifer Eckhart’s family never wanted to hear. The former Fox News staff member was found dead inside the bathroom of her...
Mahershala Ali Says ‘I Agree’ That Marvel Not Making ‘Blade’ Is the ‘Biggest Failure’ of Kevin Feige’s Career: ‘I Don’t Know Why It Didn’t Happen’
Mahershala Ali is dumbfounded like the rest of us when it comes to Marvel’s inability to get his “Blade” movie reboot off the ground. Marvel Studios president Kevin Feige told the “Happy Sad Confused” podcast over the summer that he was “feeling like a gigantic loser and failure” for bungling Ali’s “Blade,” and now the […]
Mary Beth Barone Writes & Stars Opposite Joe Alwyn In Rom-Com ‘Still We Met’; Lena Dunham Among EPs
EXCLUSIVE: Mary Beth Barone, the comedic multi-hyphenate who just set up the A24 rom-com series Hard Feelings at Hulu, has written and will star opposite Hamnet‘s Joe Alwyn in Still We Met, an original romantic comedy loosely inspired by her own experiences. Marking the narrative feature directorial debut of Zackary Drucker, the filmmaker behind the […]
5 Things the Fall Festivals Told Us About the Oscar Race, From Julianne Moore and John Malkovich to ‘La Bola Negra’ and ‘I Play Rocky’
The fall festival triple crown ended the way it always does, with a Toronto audience getting the last word. On Sunday, those words were in Spanish. “La Bola Negra,” the sprawling Netflix epic from Los Javis, took TIFF’s People’s Choice Award, capping three weeks in which Venice handed its Golden Lion to May el-Toukhy’s “Woman […]
Why Taylor Swift Performing at VMAs 2026 Can Be a Huge Moment for Both Her Fans & MTV
Taylor Swift just announced her new single “Patient Zero” is arriving on September 25, two days before the 2026 MTV […] The post Why Taylor Swift Performing at VMAs 2026 Can Be a Huge Moment for Both Her Fans & MTV appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
Maks Chmerkovskiy, Peta Murgatroyd Tease New Dance Project After Move
Maks Chmerkovskiy and Peta Murgatroyd can only keep their dancing shoes off for so long. Three months after the former Dancing with the Stars pros detailed their cross country move from...
Was Mary Magdalene a Sinner or a Saint? Artists Weigh In
A new exhibition at the Städel Museum in Frankfurt traces her shifting image over the centuries.
White House’s Trump TV 24-Hour Livestream, Launched After He Banned CNN and MS NOW, Slammed by Critics as ‘Literally State-Run TV’
President Donald Trump has banned CNN, MS NOW and Politico from White House coverage, and the three outlets are suing him, alleging it abridges their First Amendment rights. In response to Trump’s ban of the news outlets, ABC News, CBS News, NBC News and Fox News — which along with CNN provide the White House […]
Roshan Sethi’s ‘The Surgeon’ Acquired by Sony Pictures for North America and Beyond
Sony Pictures has acquired North American rights to Toronto breakout “The Surgeon,” in what the studio characterized as a “highly competitive situation.” Sony also acquired rights in Latin America, Italy, China and Hong Kong to the film from Roshan Sethi, the director of “A Nice Indian Boy” and “The Resident,” who is also a practicing […]
Sony Scoops Up TIFF Michelle Yeoh Thunder Road Action Thriller ‘The Surgeon’
In another sign of life for films looking for acquisitions out of film festivals, the Thunder Road and Tango thriller The Surgeon starring Oscar winner Michelle Yeoh is seeing its North American and some foreign rights won by Sony Pictures after multiple bids. Sony also took rights in Latin America, Italy, China, and Hong Kong. […]
Lionel Richie undergoes heart procedure amid stop-and-go tour with Earth, Wind & Fire
Lionel Richie and his tour with Earth, Wind & Fire hit yet another health-related roadblock this week. He was hospitalized to receive treatment for an irregular heartbeat.
Princess Diana Made Eerie Funeral Premonition 2 Months Before Death
A harmless joke made by Princess Diana has devastating undertones after her death. In Charles Spencer’s new book, Swan Song: Diana, My Sister, the late Princess of Wales’ younger brother detailed...
Recommended
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.